A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Qilu Pharmaceutical Co., Ltd.
Arcus Biosciences, Inc.
City of Hope Medical Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
AstraZeneca